OPTIMAL-PSMA:剂量强化与标准方案对比的2期随机对照试验
OPTIMAL-PSMA是一项2期、开放标签、双臂、多中心随机对照试验,计划纳入120例mCRPC患者,按2:1随机接受[177Lu]Lu-PSMA-597剂量强化方案(第1、3、15天及第10、20、30周给药,共6次,基于中期安全评估选用7.5或8.5 GBq)或标准方案(每6周7.5 GBq,最多6次)。主要终点为PSA下降≥90%,关键次要终点包括强化剂量安全性、PSA下降≥50%、影像学与PSA无进展生存期及总生存期。
要点
- 剂量强化方案为早期密集诱导后维持,标准方案为每6周7.5 GBq最多6次。
- 主要终点为PSA下降≥90%,同时评估安全性与生存终点。
- 入选需PSMA PET/CT阳性且ARPI治疗后进展,不适合或已接受多西他赛。
核心结论
- 本研究将确定[177Lu]Lu-PSMA-597剂量强化方案是否安全,并较标准方案改善缓解深度与生存结局。
研究设计与样本
- 2期、开放标签、双臂、多中心随机对照试验,计划纳入120例mCRPC患者并按2:1随机分组。
关键数值与推荐
- arm 1接受第1、3、15天及第10、20、30周共6次剂量强化给药,单次剂量基于中期安全评估为7.5或8.5 GBq。
- arm 2接受标准剂量7.5 GBq每6周一次,直至无临床获益,最多6次。
- 主要终点为PSA下降≥90%,关键次要终点包括强化剂量安全性、PSA下降≥50%、影像学与PSA无进展生存期及总生存期。
临床怎么用
- 入组患者需为ARPI治疗后进展的mCRPC,已接受或不适合多西他赛化疗,且PSMA PET/CT显示PSMA高表达病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OPTIMAL-PSMA aims to determine the safety and efficacy of a dose-intensified (intense induction followed by a maintenance period) regimen of [177Lu]Lu-PSMA-597 compared with the standard-of-care regimen (every 6 wk for up to 6 doses) in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: OPTIMAL-PSMA is a phase 2, open-label, 2-arm, multicenter, randomized controlled trial of [177Lu]Lu-PSMA-597, a novel prostate-specific membrane antigen (PSMA) peptide with low nontarget organ dosimetry. A total of 120 patients with mCRPC will be enrolled and randomized 2:1 to receive either a dose-intensified regimen (arm 1) or the standard-of-care regimen (arm 2) of [177Lu]Lu-PSMA-597. Eligible participants must have mCRPC with disease progression after androgen receptor pathway inhibitor therapy, have received or are not considered medically fit for docetaxel chemotherapy, and demonstrate PSMA-avid disease on PET/CT. Participants assigned to arm 1 will receive early intensified [177Lu]Lu-PSMA-597 dosing (7.5 or 8.5 GBq on the basis of an interim safety assessment) on days 1, 3, and 15 and during weeks 10, 20, and 30 (6 doses). All participants in arm 2 will receive the standard dose of 7.5 GBq of [177Lu]Lu-PSMA-597 administered every 6 wk until they are no longer clinically benefiting, for a maximum of 6 doses. Clinical and laboratory safety assessments will be conducted 3 times weekly, with diagnostic CT and bone scans performed at 8 wk and then every 12 wk until radiographic progression. Translational studies incorporate serial multiple-time-point circulating tumor DNA matched with SPECT/CT dosimetry at each time point and PSMA PET at baseline and 8 wk for correlation with clinical outcomes. The primary endpoint is a 90% or greater decline in prostate-specific antigen (PSA) level. Key secondary endpoints include the safety of intensified dosing, a 50% or greater decline in PSA level, radiographic and PSA progression-free survival, and overall survival. Translational endpoints include evaluation of serial circulating tumor DNA, biologic effective dose with intensified versus standard dosing of [177Lu]Lu-PSMA-597, and evaluation of serial SPECT/CT and PSMA PET/CT for treatment response. Conclusion: OPTIMAL-PSMA will determine whether a dose-intensified regimen of [177Lu]Lu-PSMA-597 is safe and improves depth of response and survival outcomes compared with the standard dosing regimen. The results of this study may redefine the optimal treatment scheduling for PSMA-targeted radiopharmaceutical therapy for patients with mCRPC.
引用
- Khan S, Papa N, Hioki T, et al. A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA). J Nucl Med. 2026. PMID: 42532645. doi:10.2967/jnumed.126.272714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。